Cobicistat

Major

Cobicistat Bosutinib Bosulif Increased bosutinib exposure Details Cobicistat Brexpiprazole Rexulti Increased brexpiprazole exposure Details Cobicistat Brigatinib Alunbrig Increased brigatinib exposure Details Cobicistat Brivaracetam Briviact Reduced cobicistat exposure Details Cobicistat Brivaracetam Injection Briviact Reduced cobicistat exposure Details Cobicistat Budesonide Entocort Increased budesonide exposure and increased risk for systemic corticosteroid effects Details Cobicistat Budesonide Nasal Spray Rhinocort Increased budesonide exposure and increased risk for systemic corticosteroid effects Details Cobicistat Budesonide Oral Inhalation Pulmicort Increased budesonide exposure and increased risk for systemic corticosteroid effects Details Cobicistat Cabazitaxel Injection Jevtana Increased cabazitaxel exposure Details Cobicistat Cabozantinib Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Cobicistat Cabozantinib (Thyroid Cancer) Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Cobicistat Calcifediol Rayaldee Altered serum levels of calcifediol Details Cobicistat Ciclesonide Nasal Spray Omnaris Increased ciclesonide exposure and an increased risk for systemic corticosteroid effects Details Cobicistat Ciclesonide Oral Inhalation Alvesco Increased ciclesonide exposure and an increased risk for systemic corticosteroid effects Details Cobicistat Clopidogrel Plavix Potential reduction of the antiplatelet activity of clopidogrel Details Cobicistat Cobimetinib Cotellic Increased cobimetinib exposure Details Cobicistat Cyclophosphamide Cytoxan® Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Cobicistat Cyclophosphamide Injection Cytoxan® Injection Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Cobicistat Cyclosporine Injection Atopica Increased cycloSPORINE exposure and an increased cobicistat exposure Details Cobicistat Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure and an increased cobicistat exposure Details Cobicistat Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Cobicistat Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Cobicistat Dasatinib Phyrago Increased dasatinib exposure and an increased risk of dasatinib-related adverse effects Details Cobicistat Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Cobicistat Dexamethasone Injection Decadron Reduced cobicistat exposure and increased dexAMETHasone exposure Details Cobicistat Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced cobicistat exposure and increased dexAMETHasone exposure Details Cobicistat Diazepam Nasal Spray Valtoco Increased diazepam exposure Details Cobicistat Diazepam Rectal Diastat Increased diazepam exposure Details Cobicistat Didanosine Videx® Increased risk of adverse effects Details Cobicistat Digoxin Cardoxin® Increased digoxin exposure Details Cobicistat Disopyramide Norpace Increased disopyramide exposure Details Cobicistat Docetaxel Beizray Increased DOCEtaxel exposure Details Cobicistat Docetaxel Injection Beizray Increased DOCEtaxel exposure Details Cobicistat Edoxaban Savaysa Increased edoxaban exposure Details Cobicistat Elacestrant Orserdu Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Cobicistat Encorafenib Braftovi Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Cobicistat Entrectinib Rozlytrek Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Cobicistat Erdafitinib Balversa Increased erdafitinib exposure Details Cobicistat Erlotinib Tarceva Increased erlotinib exposure and risk of toxicity Details Cobicistat Everolimus Afinitor Increased everolimus exposure and an increased cobicistat exposure Details